Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JSI-1187 Capsule in the Treatment of Advanced Solid Tumors With MAPK Signaling Pathway Mutations

NCT06239623 is registered in ClinicalTrials.gov with JS InnoPharm, LLC as lead sponsor.

NCT NCT06239623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JSI-1187 Capsule in the Treatment of Advanced Solid Tumors With MAPK Signaling Pathway Mutations
Lead sponsor
JS InnoPharm, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
April 2, 2022
Completion date
December 30, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, nsclc, solid tumor